Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

52.0%

13 terminated/withdrawn out of 25 trials

Success Rate

43.5%

-43.1% vs industry average

Late-Stage Pipeline

8%

2 trials in Phase 3/4

Results Transparency

160%

16 of 10 completed trials have results

Key Signals

1 recruiting16 with results13 terminated

Enrollment Performance

Analytics

Phase 2
13(59.1%)
Phase 1
6(27.3%)
Phase 4
2(9.1%)
N/A
1(4.5%)
22Total
Phase 2(13)
Phase 1(6)
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT07103746Phase 2Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Role: collaborator

NCT05285891Phase 4Active Not Recruiting

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Role: collaborator

NCT05000216Phase 2Terminated

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Role: collaborator

NCT03093402Phase 2Completed

JBT-101 in Systemic Lupus Erythematosus (SLE)

Role: collaborator

NCT04918147Phase 2Terminated

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Role: collaborator

NCT02603146Phase 2Terminated

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

Role: collaborator

NCT04588363Completed

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

Role: collaborator

NCT03239470Phase 1Terminated

Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

Role: collaborator

NCT01086540Phase 2Completed

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Role: collaborator

NCT00302952Phase 2Terminated

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Role: collaborator

NCT00837434Phase 4Completed

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

Role: collaborator

NCT02330965Completed

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

Role: collaborator

NCT01946880Phase 2Terminated

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

Role: collaborator

NCT02428309Phase 1Terminated

Autologous Polyclonal Tregs for Lupus

Role: collaborator

NCT01552681Phase 2Terminated

Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

Role: collaborator

NCT00283712Phase 2Completed

Use of Infliximab for the Treatment of Pemphigus Vulgaris

Role: collaborator

NCT00036491Phase 1Completed

Anti-CD20 in Systemic Lupus Erythematosus

Role: collaborator

NCT00101829Phase 1Completed

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

Role: collaborator

NCT00710021Phase 2Completed

Vitamin D3 in Systemic Lupus Erythematosus

Role: collaborator

NCT01953354Phase 2Terminated

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

Role: collaborator